Page 386 - ONLINE PROCEEDING BOOK WSAVA 2017
P. 386

386
An Urban Experience
Automated bone marrow cell counting methods have been reported and may add more precision to bone marrow evaluation in the future. Furthermore novel biomarkers including miRNA, proteome determinations, molecular expression patterns in hematologic malignancies, detection of circulating cancer cells and other liquid biopsy parametersall may become part of the routine management of canine and feline cancer patients in the future.
Selected references
Veterinary cooperative oncology group - common terminology criteria for adverse events (VCOG-CTCAE) following chemotherapy or biological antineoplastic therapy in dogs and cats v1.1.[No authors listed]. Vet Comp Oncol. 2016 Dec;14(4):417-446.
Kristensen AT, Wiinberg B et al. Evaluation of Human Recombinant Tissue Factor- Activated
Thromboelastography in 49 Dogs with Neoplasia. J Vet Intern Med 2008;22:140– 147.
Rishniw M, Pion PD. Evaluation of performance of veterinary in-clinic hematology analyzers. Vet Clin Path, 2016 (dec);45:604-14.
Schwartz D, Sharkey L, et al. Platelet volume and plateletcrit in dogs with presumed primary immune-mediated thrombocytopenia. J Vet Intern Med. 2014 Sep-Oct;28(5):1575-9.
Fujino Y, Nakamura Y, et al. Development and evaluation of a novel in-clinic automated hematology analyzer, ProCyte Dx, for canine erythrocyte indices, leukogram, platelet counts and reticulocyte counts.
J Vet Med Sci. 2013 Nov;75(11):1519-24.
42ND WORLD SMALL ANIMAL VETERINARY ASSOCIATION CONGRESS AND FECAVA 23RD EUROCONGRESS


































































































   384   385   386   387   388